STOCK TITAN

Bio-Techne (TECH) SVP exercises 2,259 RSUs, 740 shares withheld

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Bio-Techne Corp senior vice president and general counsel Shane Bohnen reported routine equity compensation activity. On April 3, 2026, he exercised restricted stock units into 2,259 shares of common stock. Of these, 740 shares were withheld at $53.13 per share to cover tax obligations, leaving him with 5,904 common shares held directly. He also continues to hold multiple stock option and restricted stock unit awards that can convert into additional Bio-Techne common shares over time.

Positive

  • None.

Negative

  • None.
Insider Bohnen Shane
Role SVP - General Counsel
Type Security Shares Price Value
Exercise Restricted Stock Units 2,259 $0.00 --
Exercise Common Stock 2,259 $0.00 --
Tax Withholding Common Stock 740 $53.13 $39K
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Restricted Stock Units -- -- --
holding Performance Restricted Stock Units -- -- --
holding Performance Stock Option (Right to Buy) -- -- --
holding Performance Restricted Stock Units -- -- --
holding Restricted Stock Units -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Performance Restricted Stock Units -- -- --
holding Restricted Stock Units -- -- --
holding Stock Option (Right to Buy) -- -- --
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Common Stock — 6,644 shares (Direct); Stock Option (Right to Buy) — 8,848 shares (Direct); Performance Restricted Stock Units — 4,802 shares (Direct); Performance Stock Option (Right to Buy) — 12,924 shares (Direct)
Footnotes (1)
  1. Fully exercisable. Options to purchase 876 shares vest on each of 8/15/2023, 8/15/2025 and 8/15/2026, and options to purchase 880 shares vest on 8/15/2024. Options to purchase 982 shares vest on each of 4/3/2024, 4/3/2025, 4/3/2026 and 4/3/2027. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. 2,259 restricted stock units vest on 4/3/2026. Options to purchase 4,076 shares vest on 8/15/2024 and 8/15/2026, and options to purchase 4,075 shares vest on 8/15/2025 and 8/15/2027. 49 restricted stock units vest on 8/15/2026. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). 1,669 restricted stock units vest on each of 8/15/2026 and 8/15/2027. Options to purchase 3,372 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). 2,332 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. Options to purchase 5,966 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 5,965 shares vest on 8/15/2028.
RSUs converted 2,259 shares Restricted Stock Units converted into common stock on April 3, 2026
Tax-withheld shares 740 shares Shares withheld at $53.13 per share for tax obligations
Share price for withholding $53.13 per share Value used for 740-share tax-withholding disposition
Shares after transaction 5,904 shares Common stock directly owned following April 3, 2026 transactions
Option position 1 8,848 shares at $47.60 Stock option right to buy common stock, expiring August 7, 2026
Option position 2 8,944 shares at $66.97 Stock option right to buy common stock, expiring August 5, 2027
Performance RSUs 13,992 units Performance Restricted Stock Units linked to common stock
Latest option grant 17,897 shares at $53.60 Stock option right to buy common stock, expiring August 15, 2035
Restricted Stock Units financial
""security_title": "Restricted Stock Units""
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax-withholding disposition financial
""transaction_action": "tax-withholding disposition""
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
Performance Restricted Stock Units financial
""security_title": "Performance Restricted Stock Units""
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
Stock Option (Right to Buy) financial
""security_title": "Stock Option (Right to Buy)""
derivative exercise/conversion financial
""transaction_action": "derivative exercise/conversion""
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bohnen Shane

(Last)(First)(Middle)
614 MCKINLEY PLACE NE

(Street)
MINNEAPOLIS MINNESOTA 55413

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP - General Counsel
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/03/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/03/2026M2,259A$06,644D
Common Stock04/03/2026F740D$53.135,904D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$47.6 (1)08/07/2026Common Stock8,8488,848D
Stock Option (Right to Buy)$66.97 (1)08/05/2027Common Stock8,9448,944D
Stock Option (Right to Buy)$120.46 (1)08/06/2028Common Stock3,4603,460D
Stock Option (Right to Buy)$94.52 (2)08/15/2029Common Stock3,5083,508D
Stock Option (Right to Buy)$73.76 (3)04/03/2030Common Stock3,9283,928D
Restricted Stock Units(4)04/03/2026M2,259 (5) (5)Common Stock2,259$00D
Stock Option (Right to Buy)$84.61 (6)08/15/2030Common Stock16,30216,302D
Restricted Stock Units(4) (7) (7)Common Stock4949D
Performance Restricted Stock Units(4) (8) (8)Common Stock4,8024,802D
Performance Stock Option (Right to Buy)$84.61 (8) (8)Common Stock12,92412,924D
Performance Restricted Stock Units(4) (9) (9)Common Stock10,01210,012D
Restricted Stock Units(4) (10) (10)Common Stock3,3383,338D
Stock Option (Right to Buy)$74.91 (11)08/15/2034Common Stock13,48813,488D
Performance Restricted Stock Units(4) (12) (12)Common Stock13,99213,992D
Restricted Stock Units(4) (13) (13)Common Stock6,9966,996D
Stock Option (Right to Buy)$53.6 (14)08/15/2035Common Stock17,89717,897D
Explanation of Responses:
1. Fully exercisable.
2. Options to purchase 876 shares vest on each of 8/15/2023, 8/15/2025 and 8/15/2026, and options to purchase 880 shares vest on 8/15/2024.
3. Options to purchase 982 shares vest on each of 4/3/2024, 4/3/2025, 4/3/2026 and 4/3/2027.
4. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
5. 2,259 restricted stock units vest on 4/3/2026.
6. Options to purchase 4,076 shares vest on 8/15/2024 and 8/15/2026, and options to purchase 4,075 shares vest on 8/15/2025 and 8/15/2027.
7. 49 restricted stock units vest on 8/15/2026.
8. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
9. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
10. 1,669 restricted stock units vest on each of 8/15/2026 and 8/15/2027.
11. Options to purchase 3,372 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
12. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
13. 2,332 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
14. Options to purchase 5,966 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 5,965 shares vest on 8/15/2028.
/s/ Shane Bohnen04/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did BIO-TECHNE (TECH) report for Shane Bohnen?

BIO-TECHNE reported that SVP and general counsel Shane Bohnen exercised restricted stock units into 2,259 shares of common stock. As part of this event, 740 shares were withheld to satisfy tax obligations, and he now directly holds 5,904 common shares.

How many BIO-TECHNE (TECH) shares does Shane Bohnen hold after this Form 4?

After these transactions, Shane Bohnen directly holds 5,904 shares of BIO-TECHNE common stock. This figure reflects the net position following the conversion of restricted stock units and the 740-share tax-withholding disposition reported on April 3, 2026.

What was the purpose of the 740 BIO-TECHNE (TECH) shares disposed by Shane Bohnen?

The 740 BIO-TECHNE shares were not an open-market sale. They were withheld at $53.13 per share to cover tax liabilities arising from the vesting and conversion of 2,259 restricted stock units into common stock on April 3, 2026.

Did Shane Bohnen buy or sell BIO-TECHNE (TECH) shares on the open market?

The filing shows no open-market purchases or sales. Activity consists of exercising 2,259 restricted stock units into common shares and a tax-withholding disposition of 740 shares at $53.13 per share to satisfy related tax obligations.

What stock options and RSUs does Shane Bohnen still hold at BIO-TECHNE (TECH)?

Shane Bohnen retains several stock options and restricted stock units. These include options with exercise prices such as $47.60, $66.97, and $120.46, and multiple performance and time-based RSU grants that together cover tens of thousands of underlying BIO-TECHNE shares.

How many BIO-TECHNE (TECH) restricted stock units vested for Shane Bohnen in this event?

The filing reports that 2,259 restricted stock units converted into an equal number of BIO-TECHNE common shares. A related footnote explains that each restricted stock unit represents a right to receive one share of common stock, and these units vested on April 3, 2026.